ClinicalTrials.gg
TerminatedNCT01944969Updated Oct 17, 2018Results posted

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

A Phase 3 interventional study of Brexpiprazole in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated because the lead-in study (14571A) in elderly was terminated; see Detailed Description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
20th of 24
26 · median 189
Started
2013
with 6 others
Phase 3
16 of 24
none open now
Registered
11th of 24
by date
Lead sponsor
4 of 24
H. Lundbeck A/S

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 20th largest by enrollment, is one of 7 that started in 2013, is one of 16 in phase 3, and was the 11th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in patients with Major Depressive Disorder (MDD)

Read the detailed description

This extension safety study was terminated early because one of the lead-in studies (14571A) in elderly was terminated and because the Sponsor considered that sufficient long-term safety data has already been collected in the development programme in the population aged 18-65 yrs.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is judged to benefit from adjunctive treatment with brexpiprazole according to the clinical opinion of the investigator.
  • The patient had MDD at entry in lead-in brexpiprazole studies, NCT01838681 / 14570A or NCT01837797 / 14571A, diagnosed according to ™.
  • The patient agrees to protocol-defined use of effective .

Exclusion criteria

Exclusion Criteria:

  • The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
  • The patient has been diagnosed with a psychiatric disorder other than MDD during the lead-in studies NCT01838681 / 14570A or NCT01837797 / 14571A.
  • The patient, in the opinion of the investigator or according to C-SSRS, is at significant risk of suicide.
  • The patient has any relevant medical history or current presence of systemic disease.
  • The patient has, at the Baseline Visit an abnormal that is, in the investigator's opinion, .
  • The patient has a moderate or severe ongoing adverse event related to study medication from the lead-in studies considered of potential safety risk by the investigator.
  • The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)

    Drug: Brexpiprazole

Interventions

  • 1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    Number of participants with Treatment-Emergent Adverse Events

    Time frame: From baseline to Week 52

  2. Number of Withdrawals

    Number of withdrawals

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)

    The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour. The electronic C-SSRS (eC-SSRS) is a patient-rated electronic version using interactive voice response technology. A structured CSSRS script of standardised questions, follow-up prompts, error-handling and scoring conventions is used for administration.

    Time frame: From baseline to Week 52

  2. Change in Depressive Symptoms

    The Montgomery and Aasberg Depression Rating Scale (MADRS) total score

    Time frame: From baseline to Week 52

  3. Proportion of Patients in Remission

    Based on a pre-specified MADRS total score

    Time frame: From baseline to Week 52

  4. Change in Clinical Global Impression

    Clinical Global Impression - Severity of illness (CGI-S) score

    Time frame: From baseline to Week 52

  5. Change in Health-related Quality of Life

    Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-(SF)) total score

    Time frame: From baseline to Week 52

  6. Change in Health-related Quality of Life

    The EuroQoL 5 Dimensions 5L version (EQ-5D-5L) Visual Analogue Scale (VAS) is a patient-reported assessment designed to measure the patient's wellbeing. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analogue scale (VAS) of the overall health state. Each descriptive item is rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems) and a single summary index (from 0 to 1) can be calculated. The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline and Week 52

07

Results

Posted Mar 3, 2016
Limitations and caveats
Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.

Participant flow

Participant flow — Overall Study
MilestoneBrexpiprazole and ADT
Started26
Completed0
Not completed26
Withdrew: Adverse event1
Withdrew: Lack of efficacy1
Withdrew: Non-compliance with imp1
Withdrew: Administrative or other reasons23

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events

Number of participants with Treatment-Emergent Adverse Events

Time frame:
From baseline to Week 52
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events
participantsBrexpiprazole and ADT
Number of Participants With Treatment-Emergent Adverse Events28
PrimaryNumber of Withdrawals

Number of withdrawals

Time frame:
From baseline to Week 52
Reported as:
Number · participants
Number of Withdrawals
participantsBrexpiprazole and ADT
Number of Withdrawals26
SecondaryNumber of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)

The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour. The electronic C-SSRS (eC-SSRS) is a patient-rated electronic version using interactive voice response technology. A structured CSSRS script of standardised questions, follow-up prompts, error-handling and scoring conventions is used for administration.

Time frame:
From baseline to Week 52
Reported as:
Number · participants
Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
participantsBrexpiprazole and ADT
No suicidal ideation or behaviour25
Any non-suicidal self-injurious behavior0
Suicidal Ideation1
Preparatory action towards imminent suicidal0
Not fatal suicide attempt0
Completed suicide0
SecondaryChange in Depressive Symptoms

The Montgomery and Aasberg Depression Rating Scale (MADRS) total score

Time frame:
From baseline to Week 52

No measurements were reported for this outcome.

SecondaryProportion of Patients in Remission

Based on a pre-specified MADRS total score

Time frame:
From baseline to Week 52

No measurements were reported for this outcome.

SecondaryChange in Clinical Global Impression

Clinical Global Impression - Severity of illness (CGI-S) score

Time frame:
From baseline to Week 52

No measurements were reported for this outcome.

SecondaryChange in Health-related Quality of Life

Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-(SF)) total score

Time frame:
From baseline to Week 52

No measurements were reported for this outcome.

SecondaryChange in Health-related Quality of Life

The EuroQoL 5 Dimensions 5L version (EQ-5D-5L) Visual Analogue Scale (VAS) is a patient-reported assessment designed to measure the patient's wellbeing. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analogue scale (VAS) of the overall health state. Each descriptive item is rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems) and a single summary index (from 0 to 1) can be calculated. The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline and Week 52

No measurements were reported for this outcome.

Adverse events

Collected over From baseline to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole and ADT—0/26 (0%)5/26 (19.2%)
Most frequent other events
Most frequent other events
EventBrexpiprazole and ADT
Accidental overdoseInjury, poisoning and procedural complications3/26
LethargyNervous system disorders2/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Brexpiprazole and ADT
<=18 years0
Between 18 and 65 years3
>=65 years23
Age, Continuous
Age, Continuous(years)Brexpiprazole and ADT
Mean66.12 ± 10.03
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole and ADT
Female21
Male5
Region of Enrollment
Region of Enrollment(participants)Brexpiprazole and ADT
United States14
Slovakia2
Sweden2
United Kingdom1
Estonia3
Finland2
Germany2
08

Study locations

1 site
  • US008
    Orlando, Florida 32806, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2013
First posted
Sep 18, 2013
Start
Oct 2013
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Mar 3, 2016
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01944969
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Sep 18, 2013
Start date
Oct 2013
Primary completion
May 2014
Completion
May 2014
Results posted
Mar 3, 2016
Last update
Oct 17, 2018

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion